Cadence Pharmaceuticals Inc. Sustainability Profile
Cadence Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has made significant strides in developing innovative therapies, particularly in pain management and anaesthesia. Cadence is renowned for its flagship product, OFIRMEV, an intravenous formulation of acetaminophen, which has transformed pain relief protocols in hospitals. With a focus on enhancing patient care, Cadence Pharmaceuticals has established a strong market position, recognised for its commitment to quality and efficacy. The company operates primarily in North America, with a growing presence in international markets. Cadence's dedication to research and development continues to drive its success, positioning it as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does Cadence Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cadence Pharmaceuticals Inc.'s score of 38 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cadence Pharmaceuticals Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Mallinckrodt plc, which may influence its climate commitments and reporting practices. As of now, Cadence Pharmaceuticals has not established any documented reduction targets or initiatives related to carbon emissions. This lack of specific targets suggests that the company may be in the early stages of developing a comprehensive climate strategy. Given the context of its parent company, Mallinckrodt plc, it is important to note that emissions data and climate commitments may be cascaded from this higher-level organisation. However, no specific emissions data or reduction initiatives from Mallinckrodt plc have been detailed in the provided information. In summary, while Cadence Pharmaceuticals Inc. does not currently report emissions or reduction targets, its relationship with Mallinckrodt plc may play a role in shaping its future climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 89,551,000 | 00,000,000 |
| Scope 2 | 82,347,000 | 00,000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Cadence Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Cadence Pharmaceuticals Inc.'s Location?
Cadence Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cadence Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
